PLoS Genet:激活这个蛋白,便有望抵御阿兹海默病

2017-03-10 佚名 药明康德

日前,英国伦敦大学学院 (University College London) 的研究人员发现,一种称为 Keap1 的蛋白可能预防阿兹海默病 (Alzheimer’s Disease, AD) 和其它神经退行性疾病的新靶点。Keap1 的作用是抑制具有保护神经元功能的 Nrf2 蛋白。通过抑制 Keap1 的功能,研究人员能够激活 Nrf2 蛋白功能,保护神经细胞在病理环境下不受损伤。

日前,英国伦敦大学学院 (University College London) 的研究人员发现,一种称为 Keap1 的蛋白可能预防阿兹海默病 (Alzheimer’s Disease, AD) 和其它神经退行性疾病的新靶点。Keap1 的作用是抑制具有保护神经元功能的 Nrf2 蛋白。通过抑制 Keap1 的功能,研究人员能够激活 Nrf2 蛋白功能,保护神经细胞在病理环境下不受损伤。

目前对 AD 的治疗仍然停留在缓解 AD 症状的层次上,市场上没有任何药物能够防止 AD 的产生或者阻止病情的进一步恶化。Nrf2 转录因子因为能够保护大脑细胞在应激条件下不受损伤而获得了研究人员的关注 。而细胞应激增强是多种神经退行性疾病的重要特征。在 AD 患者中,Nrf2 的功能受到抑制。因此,研究人员试图通过提高 Nrf2 的表达量或激活 Nrf2 的功能来治疗神经退行性疾病。

▲Keap1 与 Nrf2 相互作用机制(图片来源:《PLOS Genetics》)

强有力的 Nrf2 激活剂已经被开发出来,并且在 AD 小鼠模型中证明可以起到保护神经细胞不受神经毒性损伤并且改善记忆缺陷的作用。但是这些激活剂由于脱靶效应也带来了严重的毒副作用,而且过度激活 Nrf2 也会带来其它的副作用。因此,找到一种副作用最小的激活 Nrf2 的方法是研究人员需要解决的课题。

在这项发表在《PLOS Genetics》的研究中,研究人员在果蝇模型中发现β- 淀粉样蛋白 (β-Amyloid) 会抑制 Nrf2 功能。Keap1 是天然的 Nrf2 抑制因子。当研究人员用遗传学方法在果蝇模型中降低 Keap1 的表达量时,他们发现这可以增强 Nrf2 活性并且降低淀粉样蛋白带来的细胞毒性。进一步研究发现降低 Keap1 水平可以在果蝇模型中增加淀粉样蛋白的降解。在小鼠细胞培养模型中,研究人员发现新开发的一款直接抑制 Keap1 与 Nrf2 结合的抑制剂可以降低淀粉样蛋白对小鼠神经细胞突触的毒性。

▲阻断 Keap1 与 Nrf2 相互作用的抑制剂(图片来源:《PLOS Genetics》)

文章的第一作者 Fiona Kerr 博士说:“我们工作的重要性在于它表明阻断 Keap1 的化合物可以提高保护细胞的 Nrf2 的活性,因此它们有可能在 AD 和其它老年痴呆症患者中防止神经细胞死亡。Keap1 可能是一个防止 AD 中神经元损伤的有效靶点。我们需要更多的工作来将这种阻断 Keap1 与 Nrf2 相互作用的抑制剂开发成为能够在动物实验中使用的药物,并且检测这种策略能否保护人类神经细胞避免由 AD 导致的损伤。”

原始出处

F Kerr,O Sofolaadesakin,D Ivanov, et al. Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.  PLoS Genetics (In press).


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1686059, encodeId=03ad1686059f2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Jun 26 03:02:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048783, encodeId=f69c2048e8323, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 25 07:02:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735471, encodeId=cc731e354712b, content=<a href='/topic/show?id=7f019e71750' target=_blank style='color:#2F92EE;'>#阿兹海默病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97717, encryptionId=7f019e71750, topicName=阿兹海默病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ff833907849, createdName=xre2019, createdTime=Sun Jan 21 00:02:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733825, encodeId=f75f1e33825f8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 25 07:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178832, encodeId=c06b1e8832e8, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/02/00cc1f8abece8e6faa16966d16e7b648.jpg, createdBy=cdf21776037, createdName=11bb77eam47(暂无昵称), createdTime=Fri Mar 10 12:27:09 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1686059, encodeId=03ad1686059f2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Jun 26 03:02:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048783, encodeId=f69c2048e8323, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 25 07:02:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735471, encodeId=cc731e354712b, content=<a href='/topic/show?id=7f019e71750' target=_blank style='color:#2F92EE;'>#阿兹海默病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97717, encryptionId=7f019e71750, topicName=阿兹海默病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ff833907849, createdName=xre2019, createdTime=Sun Jan 21 00:02:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733825, encodeId=f75f1e33825f8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 25 07:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178832, encodeId=c06b1e8832e8, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/02/00cc1f8abece8e6faa16966d16e7b648.jpg, createdBy=cdf21776037, createdName=11bb77eam47(暂无昵称), createdTime=Fri Mar 10 12:27:09 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-04-25 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1686059, encodeId=03ad1686059f2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Jun 26 03:02:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048783, encodeId=f69c2048e8323, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 25 07:02:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735471, encodeId=cc731e354712b, content=<a href='/topic/show?id=7f019e71750' target=_blank style='color:#2F92EE;'>#阿兹海默病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97717, encryptionId=7f019e71750, topicName=阿兹海默病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ff833907849, createdName=xre2019, createdTime=Sun Jan 21 00:02:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733825, encodeId=f75f1e33825f8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 25 07:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178832, encodeId=c06b1e8832e8, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/02/00cc1f8abece8e6faa16966d16e7b648.jpg, createdBy=cdf21776037, createdName=11bb77eam47(暂无昵称), createdTime=Fri Mar 10 12:27:09 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1686059, encodeId=03ad1686059f2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Jun 26 03:02:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048783, encodeId=f69c2048e8323, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 25 07:02:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735471, encodeId=cc731e354712b, content=<a href='/topic/show?id=7f019e71750' target=_blank style='color:#2F92EE;'>#阿兹海默病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97717, encryptionId=7f019e71750, topicName=阿兹海默病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ff833907849, createdName=xre2019, createdTime=Sun Jan 21 00:02:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733825, encodeId=f75f1e33825f8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 25 07:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178832, encodeId=c06b1e8832e8, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/02/00cc1f8abece8e6faa16966d16e7b648.jpg, createdBy=cdf21776037, createdName=11bb77eam47(暂无昵称), createdTime=Fri Mar 10 12:27:09 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-10-25 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1686059, encodeId=03ad1686059f2, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Jun 26 03:02:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048783, encodeId=f69c2048e8323, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 25 07:02:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735471, encodeId=cc731e354712b, content=<a href='/topic/show?id=7f019e71750' target=_blank style='color:#2F92EE;'>#阿兹海默病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97717, encryptionId=7f019e71750, topicName=阿兹海默病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ff833907849, createdName=xre2019, createdTime=Sun Jan 21 00:02:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733825, encodeId=f75f1e33825f8, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Oct 25 07:02:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=178832, encodeId=c06b1e8832e8, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/02/00cc1f8abece8e6faa16966d16e7b648.jpg, createdBy=cdf21776037, createdName=11bb77eam47(暂无昵称), createdTime=Fri Mar 10 12:27:09 CST 2017, time=2017-03-10, status=1, ipAttribution=)]
    2017-03-10 11bb77eam47(暂无昵称)

    厉害了

    0

相关资讯

Business Insider:帕金森病新型血液诊断方法准确率高达95%

  (图片摘自www.sciencealert.com) 澳大利亚科学家们最近开发出了一种能够检测帕金森症的新型血液检测方法。目前根据临床试验的数据,该检测方法的准确率高达95%。 该检测方法的工作机制是通过筛选血液中一种关键的生物标记物,从而帮助医生们在患者患病早期进行及时的诊断与治疗。 该项研究是由La Trobe大学的研究者们做出,他们已经得到包括美国Michael J.

Science:“空气污染或致痴呆”的科学研究综述

洛杉矶,加利福尼亚州——在一个位于110高速公路下风口100米处、四周密布刺铁丝网的封闭停车场内,一根铝制软管从一辆白色拖车上连接出来,其吸嘴正对着高架。该软管每分钟都会抽取上百升混有各类汽车尾气的空气,而这些尾气则排放自每天隆隆行经此处的300,000多辆汽车与柴油卡车。蜷缩在拖车内的年轻化学工程师 Afrian Saffari 打开了软管上已经被熏黑的汽缸。这一部分属于一个非常精密的过滤系

Neurology:阿兹海默症相关基因影响早期儿童的大脑发育

研究者们最近发现:与阿兹海默症发病相关的一种基因的突变能够影响儿童的大脑发育,携带该突变基因的患者在三岁左右就会表现出大脑发育障碍以及认知能力受损的症状。此前的研究表明,携带APOE基因ε4突变的的人群更加容易得老年痴呆症,但这一新的研究表明,这一基因突变还会造成早期的发育紊乱,这要比大脑斑块形成早得多。"对这些小孩子进行APOE基因的研究能够获得对老年痴呆的发生相关的更多信息" 。来自夏威夷大学

台师大团队全球首创 血清可早筛查阿兹海默症

据台湾媒体报道,阿兹海默症困扰许多家庭,且发病后难治愈。台师大团队全球首创磁减量免疫检测技术,透过血液检体早期筛选,准确率85%,比临床检验脊髓液更安全方便。 据报道,台湾师范大学今天举行学术成果发表会,由光电科技研究所讲座教授洪姮娥领导的研究团队,与台大医院神经医师科邱铭章的团队共同从事脑神经方面研究,开发血清筛检阿兹海默症技术,并技转给磁量生技股份有限公司。 洪姮娥表示,阿兹海默症困扰许多

Alzheimers Dement:新型血液检测方法可用于早期阿兹海默症的诊断

(图片摘自www.sciencealert.com) 阿兹海默症之所以是十分严重的疾病,是因为其难以避免的特性。我们没有疫苗或其它有效的预防措施,所以得不得病几乎是注定的事情。另一方面,一旦患有阿兹海默症,那么康复的几率将会很低,因为我们同样没有有效的治疗手段。 不过,如果我们能够在疾病征兆出现之前及时地诊断,这不仅仅能够帮助潜在患者延缓疾病的进程,也能帮助研究者们了解疾病的发生机制。

J Alzheimers Dis:PM2.5伤大脑?空气污染物增加患阿兹海默症风险

墨西哥蒙大拿大学(Universities of Montana)研究人员联合其他研究所的学者在最近一期的Journal of Alzheimer's Disease发表了一篇研究结果。他们发现携带载脂蛋白E(apolipoprotein E,APOE) ε4等位基因的儿童如果暴露在空气污染物之下(包括PM2.5),出现认知记忆方面的减退,患老年痴呆的风险会有所增加。APOEε4等位基因是最常见的